ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

Featured Stories

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

View Our Video

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

View the data

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View the portrait series

In the News

1112, 2020

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020

December 11th, 2020|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted Read More

912, 2020

Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020

December 9th, 2020|

Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world Read More